What are the risks and benefits of continuing a selective serotonin reuptake inhibitor (SSRI) during pregnancy?

Risks and Benefits of Continuing SSRIs in Pregnancy

For pregnant women with moderate-to-severe depression or a history of severe depression, continuing SSRIs during pregnancy is generally recommended because the absolute risks of SSRI exposure are low and appear to be outweighed by the risks of untreated maternal depression for both mother and child. 1, 2

Benefits of Continuing SSRIs

• Prevention of maternal depression relapse, which carries significant risks including increased preterm delivery, postpartum depression, and negative effects on child development 2, 3
• Treatment of moderate-to-severe depression is essential, as untreated perinatal depression is associated with high morbidity and mortality with long-term consequences on child development 4
• Maintenance of maternal mental health is critical for optimal pregnancy outcomes and maternal-infant bonding 1

Risks of SSRI Exposure (All with Low Absolute Risk)

Maternal Risks

• Small increased risk of pre-eclampsia and postpartum hemorrhage, though absolute risk remains low 5

Neonatal Risks

• No increased risk of major congenital malformations after accounting for underlying maternal illness 5, 2
• No increased risk of cardiac anomalies when compared to women with untreated depression, suggesting previous associations were due to ascertainment bias 3
• Persistent pulmonary hypertension of the newborn (PPHN) with absolute risk <1%, less than twice that in unexposed newborns, and also observed in untreated depression 2, 3
• Poor neonatal adaptation occurs in up to 25-30% of exposed neonates, but newer studies show similarly high rates among offspring of women with untreated depression 2, 3
• Small increased risk of preterm delivery and NICU admissions, though absolute risks are low 5

Neurodevelopmental Outcomes

• No increased risk of autism spectrum disorder (ASD) or ADHD after controlling for maternal psychiatric illness 1
• No increased risk of neurodevelopmental disorders in most recent evidence 5
• Mixed evidence on cognitive outcomes and affective disorders, but confounding by maternal illness remains a significant methodological challenge 5

Important Caveats

Dose Considerations

• Standard SSRI doses are not associated with adverse perinatal outcomes 6
• Sustained high doses (approximately twice the standard dose) are associated with higher placental weight, altered placental-to-birth-weight ratio, and 2-fold increased risk of NICU admission 6
• Use the minimal effective dose to balance efficacy with potential risks 2, 3

Clinical Decision-Making Algorithm

For women with mild depression of recent onset (≤2 weeks):

• Monitor and encourage exercise and social support 1

For women with mild depression not improving within 2 weeks OR moderate-to-severe depression:

• Evidence-based treatment is indicated 1
• SSRIs and psychotherapy are roughly equally effective for depression in general populations 1

For women with history of severe suicide attempts or severe depression:

• SSRIs may be superior to psychotherapy alone 1
• The risks of treatment discontinuation (relapse, postpartum depression) outweigh potential fetal/neonatal risks 2, 3

Key Pitfall to Avoid

• Do not misinterpret observational studies that fail to control for underlying maternal depression as evidence of SSRI harm—many apparent risks are actually attributable to the maternal psychiatric illness itself rather than the medication 4, 3